Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Market Access and Reimbursement Insights Report – 2025

Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Market Access and Reimbursement Insights

Thelansis’s “Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) Overview

Relapsed or refractory peripheral T‑cell lymphoma (r/r PTCL) is an aggressive and heterogeneous group of mature T‑cell non‑Hodgkin lymphomas that remain difficult to treat, as patients who relapse after initial therapy or fail to respond to frontline regimens have poor outcomes and limited long‑term survival. Conventional salvage chemotherapy offers low response rates, and only a minority of patients are eligible for potentially curative stem cell transplantation. Approved single‑agent therapies such as pralatrexate, romidepsin, and belinostat provide modest benefit, while newer approaches—including histone deacetylase inhibitors, antifolate agents, monoclonal antibodies, and immunotherapies—are under investigation. Despite these options, no consensus standard of care exists, and prognosis remains guarded, underscoring the importance of clinical trial enrollment and the urgent need for novel, disease‑modifying therapies that target the complex biology of r/r PTCL to improve durability of response and overall survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Relapsed or Refractory Peripheral T-Cell Lymphoma (r/r PTCL) – Market Access and Reimbursement Insights Report – 2025